CAM
CRSP icon

Cresset Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Cresset Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Hold
4,259
– – ﹤0.01% 1518
2026
Q1 		$203K Buy
4,259
+74
+2% +$3.9K ﹤0.01% 1468
2025
Q4 		$219K Buy
4,185
+89
+2% +$5.33K ﹤0.01% 1446
2025
Q3 		$265K Buy
+4,096
New +$235K ﹤0.01% 1295
2025
Q2 		– Sell
-10,271
Closed -$350K – 1510
2025
Q1 		$350K Sell
10,271
-4,771
-32% -$202K ﹤0.01% 1239
2024
Q4 		$592K Sell
15,042
-12,037
-44% -$568K ﹤0.01% 1008
2024
Q3 		$1.27M Sell
27,079
-3,115
-10% -$158K ﹤0.01% 1044
2024
Q2 		$1.63M Buy
30,194
+14,946
+98% +$865K 0.01% 823
2024
Q1 		$1.04M Buy
15,248
+1,611
+12% +$115K 0.01% 957
2023
Q4 		$854K Buy
13,637
+2,964
+28% +$164K 0.01% 967
2023
Q3 		$484K Sell
10,673
-49
-0.5% -$2.53K ﹤0.01% 1197
2023
Q2 		$602K Buy
+10,722
New +$608K ﹤0.01% 1184
2022
Q2 		– Sell
-3,755
Closed -$236K – 977
2022
Q1 		$236K Sell
3,755
-3,329
-47% -$209K ﹤0.01% 861
2021
Q4 		$537K Sell
7,084
-12,702
-64% -$1.11M 0.01% 674
2021
Q3 		$2.21M Buy
19,786
+670
+4% +$84.1K 0.03% 208
2021
Q2 		$3.1M Buy
19,116
+1,513
+9% +$184K 0.04% 152
2021
Q1 		$2.15M Buy
17,603
+5,423
+45% +$819K 0.03% 168
2020
Q4 		$1.86M Buy
12,180
+691
+6% +$81.7K 0.03% 168
2020
Q3 		$961K Buy
11,489
+4,743
+70% +$421K 0.02% 239
2020
Q2 		$496K Buy
+6,746
New +$394K 0.01% 343

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cresset Asset Management's CRSP Position: Q2 2026 in Review

Cresset Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 4,259 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Cresset Asset Management first reported a position in CRSP in Q2 2020 and has held it in 20 quarters since. The position peaked at $3.1M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cresset Asset Management held 4,259 shares of CRISPR Therapeutics worth $232K as of Q2 2026.
  • Cresset Asset Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1518 holding.
  • Cresset Asset Management first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • Cresset Asset Management's CRISPR Therapeutics position peaked at $3.1M in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.